References
- Pharmacist's Letter [Internet] Stockton, CA Therapeutic Research Center 2019 Proton pump inhibitors: appropriate use and safety concerns; 2019 Feb [cited 2019 Mar 27]. Available from: https://pharmacist.therapeuticre-search.com/Home/PL (#350214)
- Heidelbaugh JJ Kim AH Chang R Walker PC Overutilization of proton-pump inhibitors: what the clinician needs to know Therap Adv Gastroenterol 2012 Jul 5 4 219 32
- Katz MH Failing the acid test: benefits of proton pump inhibitors may not justify the risks for many users Arch Intern Med 2010 170 9 747 8
- Eid SM Boueiz A Paranji S Mativo C Landis R Abougergi MS Patterns and predictors of proton pump inhibitor overuse among academic and non-academic hospitalists Intern Med 2010 49 23 2561 8
- Lamberts R Brunner G Solcia E Effects of very long (up to 10 years) proton pump blockade on human gastric mucosa Digestion 2001 64 4 205 13
- Waldum HL Qvigstad G Fossmark R Kleveland PM Sandvik AK Rebound acid hyper-secretion from a physiological, pathophysiological and clinical viewpoint Scand J Gastroenterol. 2010 Apr 45 4 389 94
- Wedemeyer RS Blume H Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update Drug Saf 2014 Apr 37 4 201 11
- Ho PM Maddox TM Wang L Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome JAMA 2009 Mar 4 301 9 937 44
- Bhatt DL Cryer BL Contant CF Clopidogrel with or without omeprazole in coronary artery disease N Engl J Med 2010 Nov 11 363 20 1909 17
- Cardoso RN Benjo AM DiNicolantonio JJ Incidence of cardiovascular events and gastrointestinal bleeding in patients receiving clopidogrel with and without proton pump inhibitors: an updated meta-analysis Open Heart 2015 June 30 2 1 e00248
- Kwok CS Jeevantham V Dawn B Loke YK No consistent evidence of differential cardiovascular risk amongst proton-pump inhibitors when used with clopidogrel: meta-analysis Int J Cardiol 2013 Aug 10 167 3 965 74
- Melloni C Washam JB Jones WS Conflicting results between randomized trials and observational studies on the impact of proton pump inhibitors on cardiovascular events when co-administered with dual antiplatelet therapy: systematic review Circ Cardiovasc Qual Outcomes 2015 Jan 8 1 47 55
- Yoshihisa A Takiguchi M Kanno Y Associations of Acid Suppressive Therapy With Cardiac Mortality in Heart Failure Patients J Am Heart Assoc 2017 May 16 6 5
- Shah NH LePendu P Bauer-Mehren A Proton Pump Inhibitor Usage and the Risk of Myocardial Infarction in the General Population PLoS One 2015 Jun 10 10 6 e0124653
- Shih CJ Chen YT Ou SM Li SY Chen TJ Wang SJ Proton pump inhibitor use represents an independent risk factor for myocardial infarction Int J Cardiol 2014 Nov 15 177 1 292 7
- Xie Y Bowe B Li T Xian H Yan Y Al-Aly Z Risk of death among users of Proton Pump Inhibitors: a longitudinal observational cohort study of United States veterans BMJ Open 2017 Jul 4 7 6 e015735
- Perazella MA Proton pump inhibitors and hypomagnesemia: a rare but serious complication Kidney International 2013 Apr 83 4 553 6
- Toh JW Ong E Wilson R Hypomagnesaemia associated with long-term use of proton pump inhibitors Gastroenterol Rep (Oxf) 2015 Aug 3 3 243 53
- Leto L Aspromonte N Feola M Efficacy and safety of loop diuretic therapy in acute decompensated heart failure: a clinical review Heart Fail Rev 2014 Mar 19 2 237 46
- Wargo KA Banta WM A comprehensive review of the loop diuretics: should furosemide be first line? Ann Pharmacother 2009 Nov 43 11 1836 47
- Prescribers Digital Reference [Internet] Whippany, NJ PDR, LLC 2019 Plavix (clopidogrel bisulfate) FDA Drug Safety Communication; 2009 Nov 17 [cited 2019 Mar 28]. Available from: https://www.pdr.net/fda-drug-safety-communication/plavix?druglabelid=525&id=5033
- Ghebremariam YT LePendu P Lee JC Unexpected effect of proton pump inhibitors: elevation of the cardiovascular risk factor asymmetric dimethylarginine Circulation 2013 Aug 20 128 8 845 53
- Wilson AM Shin DS Weatherby C Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease Vasc Med 2010 Aug 15 4 267 74
- Cooke JP Flow, NO, and atherogenesis Proc Natl Acad Sci U S A 2003 Feb 4 100 3 768 70
- Yepuri G Sukhovershin R Nazari-Shafti TZ Petrascheck M Ghebre YT Cooke JP Proton Pump Inhibitors Accelerate Endothelial Senescence Circ Res 2016 Jun 10 118 12 e36 42
- Mindell JA Lysosomal acidification mechanisms Annu Rev Physiol 2012 74 69 86
- Gomm W von Holt K Thome F Association of Proton Pump Inhibitors With Risk of Dementia: A Pharmacoepidemiological Claims Data Analysis JAMA Neurol 2016 Apr 73 4 410 6
- Lazarus B Chen Y Wilson FP Proton Pump Inhibitor Use and the Risk of Chronic Kidney Disease JAMA Intern Med 2016 Feb 176 2 238 46
- Charlot M Ahlehoff O Norgaard ML Proton-pump inhibitors are associated with increased cardiovascular risk independent of clopidogrel use: a nationwide cohort study Ann Intern Med 2010 Sep 21 153 6 378 86
- Charlot M Grove EL Hansen PR Proton pump inhibitor use and risk of adverse cardiovascular events in aspirin treated patients with first time myocardial infarction: nationwide propensity score matched study BMJ 2011 May 342 d2690
- Xu J Murphy SL Kochanek KD Arias E Mortality in the United States, 2015 NCHS Data Brief 2016 Dec 267 1 8
- Kim J Blackett JW Jordokovsky D Strategies for effective discontinuation of proton pump inhibitors Curr Gastroenterol Rep 2018 May 16 20 6 27
DOI: https://doi.org/10.14797/mdcj-15-3-214 | Journal eISSN: 1947-6108
Language: English
Page range: 214 - 219
Published on: Jul 1, 2019
Published by: Houston Methodist DeBakey Heart & Vascular Center
In partnership with: Paradigm Publishing Services
© 2019 Hannah Ariel, John P. Cooke, published by Houston Methodist DeBakey Heart & Vascular Center
This work is licensed under the Creative Commons Attribution-NonCommercial 4.0 License.